Chemoprotection and ALRN-6924

We are developing ALRN-6924 as a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53-mutations to reduce or eliminate chemotherapy-induced side effects.

Preclinical Research


ALRN-6924 is a first-in-class, stabilized cell-permeating alpha-helical peptide that mimics the p53 tumor suppressor protein to disrupt its interactions with both its endogenous inhibitors, MDMX and MDM2. ALRN-6924 binds to both MDMX and MDM2 with nanomolar affinities and demonstrates evidence of specific on-target engagement in vitro by gene expression profiling and its p53-dependent effects on cells, with activity in nearly all wild-type p53 cell lines studied and no discernible effect in almost all mutant p53 cell lines.

Nonclinical research presented at the October 2019 AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics (View Poster) showed that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells while enhancing the anti-cancer activity of chemotherapy.